Genetic testing company 23andMe is laying off a large number of employees and putting a hold on developing new health treatments.
They're doing this to focus on their main business of selling genetic tests and collaborating with researchers.
23andMe has been struggling financially since a data breach in 2023, which significantly lowered its value.
The company is now exploring ways to sell or license its existing health treatment projects as part of its restructuring plan.
